These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 22573126)

  • 1. Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial.
    Hanefeld M; Pistrosch F; Koehler C; Chiasson JL
    J Hypertens; 2012 Jul; 30(7):1440-3. PubMed ID: 22573126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
    Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
    Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study.
    Bianchi C; Miccoli R; Bonadonna RC; Giorgino F; Frontoni S; Faloia E; Marchesini G; Dolci MA; Alviggi L; Gnasso A; Consoli A; Cavalot F; Cavallo MG; Leonetti F; Giaccari A; Del Prato S;
    Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):699-705. PubMed ID: 21291660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
    Chiasson JL
    Endocr Pract; 2006; 12 Suppl 1():25-30. PubMed ID: 16627376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of non-insulin-dependent diabetes mellitus and impaired glucose tolerance in two Algonquin communities in Quebec.
    Delisle HF; Ekoé JM
    CMAJ; 1993 Jan; 148(1):41-7. PubMed ID: 8439889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S; Chiasson JL
    Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors.
    Heine RJ; Nijpels G; Mooy JM
    Diabet Med; 1996; 13(3 Suppl 2):S12-4. PubMed ID: 8689855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
    Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
    Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of diabetes and pre-diabetes in a selected urban south Indian population (CUPS-19).
    Mohan V; Deepa M; Anjana RM; Lanthorn H; Deepa R
    J Assoc Physicians India; 2008 Mar; 56():152-7. PubMed ID: 18697630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the onset and progression of peripheral neuropathy and hypertension in NIDDM].
    Jarmuzewska EA; Ghidoni A
    Minerva Med; 2000; 91(1-2):1-15. PubMed ID: 10858728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study.
    Tillin T; Orchard T; Malm A; Fuller J; Chaturvedi N
    J Hypertens; 2011 Jul; 29(7):1457-62. PubMed ID: 21602709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö Preventive Trial with diet and exercise.
    Eriksson KF; Lindgärde F
    Diabetologia; 1998 Sep; 41(9):1010-6. PubMed ID: 9754818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin and hypertension. Relationship to obesity and glucose intolerance in Pima Indians.
    Saad MF; Knowler WC; Pettitt DJ; Nelson RG; Mott DM; Bennett PH
    Diabetes; 1990 Nov; 39(11):1430-5. PubMed ID: 2227116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
    Hanefeld M; Karasik A; Koehler C; Westermeier T; Chiasson JL
    Diab Vasc Dis Res; 2009 Jan; 6(1):32-7. PubMed ID: 19156626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus.
    Guerrero-Romero F; Rodríguez-Morán M
    Eur J Clin Invest; 2006 Nov; 36(11):796-802. PubMed ID: 17032347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.